{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06953089",
      "orgStudyIdInfo": {
        "id": "DB-1311-201"
      },
      "organization": {
        "fullName": "DualityBio Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors",
      "officialTitle": "A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-08",
      "overallStatus": "RECRUITING",
      "startDateStruct": {
        "date": "2025-07-18",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2030-06-30",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2030-06-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2025-04-09",
      "studyFirstSubmitQcDate": "2025-04-23",
      "studyFirstPostDateStruct": {
        "date": "2025-05-01",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2026-02-04",
      "lastUpdatePostDateStruct": {
        "date": "2026-02-06",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "DualityBio Inc.",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "BioNTech SE",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors",
      "detailedDescription": "This is a phase II, multicenter, open-label, two-part trial designed to evaluate the safety and preliminary efficacy of DB-1311 in combination with BNT327 or DB-1311 in combination with DB-1305 in targeted participants.\n\nParticipants with recurrent, progressive as well as advanced, metastatic hepatocellular carcinoma (HCC), cervical cancer (CC), melanoma, head and neck squamous cell carcinoma (HNSCC), platinum-resistant ovarian cancer (PROC) or non-small cell lung cancer (NSCLC) are eligible to participate in the trial."
    },
    "conditionsModule": {
      "conditions": [
        "Solid Tumors"
      ],
      "keywords": [
        "B7-H3",
        "PD-L1/VEGF-A",
        "TROP2 (Trophoblast cell surface antigen 2)",
        "ADC (antibody-drug conjugate)",
        "HNSCC (head and neck squamous cell carcinoma)",
        "HCC (hepatocellular carcinoma)",
        "Melanoma",
        "NSCLC(non-small cell lung cancer)",
        "OC (ovarian cancer)"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 492,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Part 1 Cohort 1A, DB-1311/BNT324+ BNT327 combination therapy",
          "type": "EXPERIMENTAL",
          "description": "Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D (Recommended Phase 2 Dose) and RP2D-1 in target population.",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        },
        {
          "label": "Part 1 Cohort 2, DB-1311/BNT324+ DB-1305 /BNT325 combination therapy",
          "type": "EXPERIMENTAL",
          "description": "Escalating combination dose levels of DB-1311/BNT324 and DB-1305/BNT325 to define RP2D and RP2D-1 in target population.",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: DB-1305/BNT325"
          ]
        },
        {
          "label": "Part 2 Arm 1: RP2D of DB-1311/BNT324 + BNT327",
          "type": "EXPERIMENTAL",
          "description": "In participants with unresectable advanced/metastatic HCC",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        },
        {
          "label": "Part 2 Arm 2: RP2D of DB-1311/BNT324 + BNT327",
          "type": "EXPERIMENTAL",
          "description": "In participants with unresectable advanced/ metastatic CC",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        },
        {
          "label": "Part2 Arm 3:RP2D of DB-1311/BNT324 + BNT327",
          "type": "EXPERIMENTAL",
          "description": "In participants with unresectable advanced/metastatic melanoma",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        },
        {
          "label": "Part 2 Arm 4: RP2D of DB-1311/BNT324 + BNT327 and RP2D-1 of DB-1311/BNT324 + BNT327",
          "type": "EXPERIMENTAL",
          "description": "In participants with recurrent/metastatic HNSCC",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        },
        {
          "label": "Part 2 Arm 5: RP2D of DB-1311/BNT324 +DB-1305/BNT325 and RP2D-1 of DB-1311/BNT324 +DB-1305/BNT325",
          "type": "EXPERIMENTAL",
          "description": "In participants with advanced/unresectable metastatic NSCLC",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: DB-1305/BNT325"
          ]
        },
        {
          "label": "Part 1 Cohort 1B, DB-1311/BNT324+ BNT327 combination therapy",
          "type": "EXPERIMENTAL",
          "description": "Escalating combination dose levels of DB-1311/BNT324 and BNT327 to define RP2D and RP2D-1 in target population.",
          "interventionNames": [
            "Drug: DB-1311/BNT324",
            "Drug: BNT327"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "DB-1311/BNT324",
          "description": "Administered I.V.",
          "armGroupLabels": [
            "Part 1 Cohort 1A, DB-1311/BNT324+ BNT327 combination therapy",
            "Part 1 Cohort 1B, DB-1311/BNT324+ BNT327 combination therapy",
            "Part 1 Cohort 2, DB-1311/BNT324+ DB-1305 /BNT325 combination therapy",
            "Part 2 Arm 1: RP2D of DB-1311/BNT324 + BNT327",
            "Part 2 Arm 2: RP2D of DB-1311/BNT324 + BNT327",
            "Part 2 Arm 4: RP2D of DB-1311/BNT324 + BNT327 and RP2D-1 of DB-1311/BNT324 + BNT327",
            "Part 2 Arm 5: RP2D of DB-1311/BNT324 +DB-1305/BNT325 and RP2D-1 of DB-1311/BNT324 +DB-1305/BNT325",
            "Part2 Arm 3:RP2D of DB-1311/BNT324 + BNT327"
          ]
        },
        {
          "type": "DRUG",
          "name": "BNT327",
          "description": "Administered I.V.",
          "armGroupLabels": [
            "Part 1 Cohort 1A, DB-1311/BNT324+ BNT327 combination therapy",
            "Part 1 Cohort 1B, DB-1311/BNT324+ BNT327 combination therapy",
            "Part 2 Arm 1: RP2D of DB-1311/BNT324 + BNT327",
            "Part 2 Arm 2: RP2D of DB-1311/BNT324 + BNT327",
            "Part 2 Arm 4: RP2D of DB-1311/BNT324 + BNT327 and RP2D-1 of DB-1311/BNT324 + BNT327",
            "Part2 Arm 3:RP2D of DB-1311/BNT324 + BNT327"
          ]
        },
        {
          "type": "DRUG",
          "name": "DB-1305/BNT325",
          "description": "Administered I.V.",
          "armGroupLabels": [
            "Part 1 Cohort 2, DB-1311/BNT324+ DB-1305 /BNT325 combination therapy",
            "Part 2 Arm 5: RP2D of DB-1311/BNT324 +DB-1305/BNT325 and RP2D-1 of DB-1311/BNT324 +DB-1305/BNT325"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Part 1: Number of participants with Dose Limiting Toxicities (DLTs).",
          "timeFrame": "During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days"
        },
        {
          "measure": "Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)",
          "timeFrame": "up to follow up period, e.g. up to 72 months."
        },
        {
          "measure": "Part 2: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs) [By arm and dose level]",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment)by arm and dose level.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Part 1: ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST 1.1 based on the investigator's assessment).",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Duration of response (DoR) per RECIST 1.1 based on the investigator's assessment.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Overall survival (OS)",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Disease-control rate (DCR) per RECIST 1.1 based on the investigator's assessment.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Time to response (TTR) per RECIST 1.1 based on the investigator's assessment.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Progression-free survival (PFS) per RECIST 1.1 based on the investigator's assessment.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with platinum-resistant ovarian cancer (PROC).",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of Part 1"
        },
        {
          "measure": "Part 1: Cancer antigen 125 (CA-125) response rate assessed per Gynecological Cancer Intergroup (GCIG) criteria in participants with PROC.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 2:Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Maximum observed concentration (Cmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Time to reach maximum observed concentration (Tmax) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with BNT327.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 total ADC, total antibody and unconjugated P1021 in combination with BNT327.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Terminal elimination half-life (t1/2) of DB-1311/BNT324 ADC, total antibody and unconjugated P1021 in combination with DB-1305/BNT325.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and 2: Anti-drug antibody (ADA) prevalence: the proportion of participants who are ADA positive at any point in time (at baseline and post-baseline).",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        },
        {
          "measure": "Part 1 and Part 2: ADA incidence: the proportion of participants having treatment-emergent ADA.",
          "timeFrame": "From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults aged ≥ 18 years or acceptable age according to local regulations at the time of voluntarily signing informed consent.\n* At least one measurable lesion as assessed by the Investigator according to RECIST v1.1 criteria.\n* Has a life expectancy of ≥ 3 months.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n* Has adequate organ function within 7 days prior to enrollment/randomization,\n* Has adequate treatment washout period prior to the first dose of trial treatment.\n\n  * For HCC patients: Histological/cytological confirmed diagnosis of HCC or clinically confirmed diagnosis of HCC; Has a Child-Pugh class A liver score.\n  * For CC patients: Has persistent, recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology\n  * For Melanoma patients: Histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic melanoma.\n  * For PROC patients (Cohort A): Participants must have a confirmed diagnosis of OC, primary peritoneal cancer, or fallopian tube cancer, all of which with high-grade serous histology. Patients must have platinum-resistant disease.\n  * For HNSCC patients: Histologically or cytologically confirmed recurrent (recurrent disease that is not amendable to curative treatment with local/ or systemic therapies)/ (disseminated) HNSCC of the oral cavity, oropharynx, hypopharynx, and larynx that is considered incurable by local therapies.\n  * For NSCLC patients: Pathologically documented Stage IIIB or IIIC NSCLC not amenable for radical surgery or definitive chemoradiation or Stage IV NSQ NSCLC. Not harboring an EGFR-sensitizing mutation or ALK gene rearrangements or other onco-driver gene mutations\n\nExclusion Criteria:\n\n* 1\\. Prior treatment with B7H3 targeted therapy.\n* Prior treatment with antibody-drug conjugate with topoisomerase inhibitor.\n* Is a candidate to locoregional treatment with potential to induce complete or near complete response and prolonged tumor control, per investigator's assessment.\n* Has an uncontrolled concomitant or intercurrent illness, that in the opinion of the investigator, contra-indicates trial participation, limits compliance with trial procedures or substantially increases the risk of incurring AEs.\n* Has uncontrolled or significant cardiovascular disease. Has clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy.\n* Has a history of (non-infectious) ILD/pneumonitis.\n* Any autoimmune, connective tissue or inflammatory disorders.\n* Has spinal cord compression or clinically active central nervous system (CNS) metastases.\n* Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Jay Ma",
          "role": "CONTACT",
          "phone": "540-808-3925",
          "email": "jay.ma@dualitybiologics.com"
        },
        {
          "name": "Qiaoli Jiang",
          "role": "CONTACT",
          "phone": "+86-15210642683",
          "email": "qiaoli.jiang@dualitybiologics.com"
        }
      ],
      "locations": [
        {
          "facility": "USA06-0",
          "status": "RECRUITING",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90025",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "USA16-0",
          "status": "RECRUITING",
          "city": "Los Angeles",
          "state": "California",
          "zip": "90025",
          "country": "United States",
          "geoPoint": {
            "lat": 34.05223,
            "lon": -118.24368
          }
        },
        {
          "facility": "USA01-0",
          "status": "RECRUITING",
          "city": "Wheat Ridge",
          "state": "Colorado",
          "zip": "80033",
          "country": "United States",
          "geoPoint": {
            "lat": 39.7661,
            "lon": -105.07721
          }
        },
        {
          "facility": "USA08-0",
          "status": "RECRUITING",
          "city": "Florida City",
          "state": "Florida",
          "zip": "99208",
          "country": "United States",
          "geoPoint": {
            "lat": 25.44789,
            "lon": -80.47922
          }
        },
        {
          "facility": "USA10-0",
          "status": "RECRUITING",
          "city": "Atlanta",
          "state": "Georgia",
          "zip": "30318",
          "country": "United States",
          "geoPoint": {
            "lat": 33.749,
            "lon": -84.38798
          }
        },
        {
          "facility": "USA11-0",
          "status": "RECRUITING",
          "city": "Bethesda",
          "state": "Maryland",
          "zip": "20817",
          "country": "United States",
          "geoPoint": {
            "lat": 38.98067,
            "lon": -77.10026
          }
        },
        {
          "facility": "USA14-0",
          "status": "RECRUITING",
          "city": "Lincoln",
          "state": "Nebraska",
          "zip": "68506",
          "country": "United States",
          "geoPoint": {
            "lat": 40.8,
            "lon": -96.66696
          }
        },
        {
          "facility": "USA04-0",
          "status": "RECRUITING",
          "city": "New York",
          "state": "New York",
          "zip": "10032",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "USA15-0",
          "status": "RECRUITING",
          "city": "Portland",
          "state": "Oregon",
          "zip": "97239",
          "country": "United States",
          "geoPoint": {
            "lat": 45.52345,
            "lon": -122.67621
          }
        },
        {
          "facility": "USA03-0",
          "status": "RECRUITING",
          "city": "Charleston",
          "state": "South Carolina",
          "zip": "29425",
          "country": "United States",
          "geoPoint": {
            "lat": 32.77632,
            "lon": -79.93275
          }
        },
        {
          "facility": "USA13-0",
          "status": "RECRUITING",
          "city": "Anderson",
          "state": "Texas",
          "zip": "46011",
          "country": "United States",
          "geoPoint": {
            "lat": 30.48715,
            "lon": -95.9869
          }
        },
        {
          "facility": "USA12-0",
          "status": "RECRUITING",
          "city": "Houston",
          "state": "Texas",
          "zip": "77030",
          "country": "United States",
          "geoPoint": {
            "lat": 29.76328,
            "lon": -95.36327
          }
        },
        {
          "facility": "USA05-0",
          "status": "RECRUITING",
          "city": "Virginia Beach",
          "state": "Virginia",
          "zip": "22031",
          "country": "United States",
          "geoPoint": {
            "lat": 36.85293,
            "lon": -75.97799
          }
        },
        {
          "facility": "USA09-0",
          "status": "RECRUITING",
          "city": "Puyallup",
          "state": "Washington",
          "zip": "98373",
          "country": "United States",
          "geoPoint": {
            "lat": 47.18538,
            "lon": -122.2929
          }
        },
        {
          "facility": "USA07-0",
          "status": "RECRUITING",
          "city": "Spokane",
          "state": "Washington",
          "zip": "99208",
          "country": "United States",
          "geoPoint": {
            "lat": 47.65966,
            "lon": -117.42908
          }
        },
        {
          "facility": "AUS07-0",
          "status": "RECRUITING",
          "city": "North Sydney",
          "state": "New South Wales",
          "zip": "2060",
          "country": "Australia",
          "geoPoint": {
            "lat": -33.839,
            "lon": 151.2072
          }
        },
        {
          "facility": "AUS06-0",
          "status": "RECRUITING",
          "city": "Benowa",
          "state": "Queensland",
          "zip": "4217",
          "country": "Australia",
          "geoPoint": {
            "lat": -28.0077,
            "lon": 153.38583
          }
        },
        {
          "facility": "AUS04-0",
          "status": "RECRUITING",
          "city": "Birtinya",
          "state": "Queensland",
          "zip": "4575",
          "country": "Australia",
          "geoPoint": {
            "lat": -26.74322,
            "lon": 153.11913
          }
        },
        {
          "facility": "AUS05-0",
          "status": "RECRUITING",
          "city": "Adelaide",
          "state": "South Australia",
          "zip": "5000",
          "country": "Australia",
          "geoPoint": {
            "lat": -34.92866,
            "lon": 138.59863
          }
        },
        {
          "facility": "CHN02-0",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100021",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "CHN13-0",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100032",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "CHN23-0",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100142",
          "country": "China",
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        },
        {
          "facility": "CHN17-0",
          "status": "RECRUITING",
          "city": "Dongguan",
          "state": "Guangdong",
          "zip": "523000",
          "country": "China",
          "geoPoint": {
            "lat": 23.01797,
            "lon": 113.74866
          }
        },
        {
          "facility": "CHN06-0",
          "status": "RECRUITING",
          "city": "Henan",
          "state": "Henan",
          "zip": "450008",
          "country": "China",
          "geoPoint": {
            "lat": 33.41499,
            "lon": 112.42212
          }
        },
        {
          "facility": "CHN12-0",
          "status": "RECRUITING",
          "city": "Xinxiang",
          "state": "Henan",
          "zip": "453100",
          "country": "China",
          "geoPoint": {
            "lat": 35.19033,
            "lon": 113.80151
          }
        },
        {
          "facility": "CHN04-0",
          "status": "RECRUITING",
          "city": "Hubei",
          "state": "Hubei",
          "zip": "430014",
          "country": "China"
        },
        {
          "facility": "CHN26-0",
          "status": "RECRUITING",
          "city": "Wuhan",
          "state": "Hubei",
          "zip": "00000",
          "country": "China",
          "geoPoint": {
            "lat": 30.58333,
            "lon": 114.26667
          }
        },
        {
          "facility": "CHN34-0",
          "status": "RECRUITING",
          "city": "Wuhan",
          "state": "Hubei",
          "zip": "430079",
          "country": "China",
          "geoPoint": {
            "lat": 30.58333,
            "lon": 114.26667
          }
        },
        {
          "facility": "CHN11-0",
          "status": "RECRUITING",
          "city": "Changsha",
          "state": "Hunan",
          "zip": "410013",
          "country": "China",
          "geoPoint": {
            "lat": 28.19874,
            "lon": 112.97087
          }
        },
        {
          "facility": "CHN16-0",
          "status": "RECRUITING",
          "city": "Xuzhou",
          "state": "Jiangsu",
          "zip": "221000",
          "country": "China",
          "geoPoint": {
            "lat": 34.20442,
            "lon": 117.28386
          }
        },
        {
          "facility": "CHN35-0",
          "status": "RECRUITING",
          "city": "Shenyang",
          "state": "Liaoning",
          "zip": "110042",
          "country": "China",
          "geoPoint": {
            "lat": 41.79222,
            "lon": 123.43278
          }
        },
        {
          "facility": "CHN25-0",
          "status": "RECRUITING",
          "city": "Xi'an",
          "state": "Shaanxi",
          "zip": "710061",
          "country": "China",
          "geoPoint": {
            "lat": 34.25833,
            "lon": 108.92861
          }
        },
        {
          "facility": "CHN04-0",
          "status": "RECRUITING",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "200032",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "CHN01-0",
          "status": "RECRUITING",
          "city": "Shanghai",
          "state": "Shanghai Municipality",
          "zip": "200120",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "CHN24-0",
          "status": "RECRUITING",
          "city": "Chengdu",
          "state": "Sichuan",
          "zip": "610041",
          "country": "China",
          "geoPoint": {
            "lat": 30.66667,
            "lon": 104.06667
          }
        },
        {
          "facility": "TWN01-0",
          "status": "RECRUITING",
          "city": "Taipei",
          "state": "Taipei",
          "zip": "0",
          "country": "Taiwan"
        },
        {
          "facility": "TWN02-0",
          "status": "RECRUITING",
          "city": "Taipei",
          "state": "Taipei",
          "zip": "23561",
          "country": "Taiwan"
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "UNDECIDED"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-10"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000077195",
          "term": "Squamous Cell Carcinoma of Head and Neck"
        },
        {
          "id": "D006528",
          "term": "Carcinoma, Hepatocellular"
        },
        {
          "id": "D008545",
          "term": "Melanoma"
        },
        {
          "id": "D002289",
          "term": "Carcinoma, Non-Small-Cell Lung"
        },
        {
          "id": "D010051",
          "term": "Ovarian Neoplasms"
        }
      ],
      "ancestors": [
        {
          "id": "D002294",
          "term": "Carcinoma, Squamous Cell"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D006258",
          "term": "Head and Neck Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D000230",
          "term": "Adenocarcinoma"
        },
        {
          "id": "D008113",
          "term": "Liver Neoplasms"
        },
        {
          "id": "D004067",
          "term": "Digestive System Neoplasms"
        },
        {
          "id": "D004066",
          "term": "Digestive System Diseases"
        },
        {
          "id": "D008107",
          "term": "Liver Diseases"
        },
        {
          "id": "D018358",
          "term": "Neuroendocrine Tumors"
        },
        {
          "id": "D017599",
          "term": "Neuroectodermal Tumors"
        },
        {
          "id": "D009373",
          "term": "Neoplasms, Germ Cell and Embryonal"
        },
        {
          "id": "D009380",
          "term": "Neoplasms, Nerve Tissue"
        },
        {
          "id": "D018326",
          "term": "Nevi and Melanomas"
        },
        {
          "id": "D012878",
          "term": "Skin Neoplasms"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D002283",
          "term": "Carcinoma, Bronchogenic"
        },
        {
          "id": "D001984",
          "term": "Bronchial Neoplasms"
        },
        {
          "id": "D008175",
          "term": "Lung Neoplasms"
        },
        {
          "id": "D012142",
          "term": "Respiratory Tract Neoplasms"
        },
        {
          "id": "D013899",
          "term": "Thoracic Neoplasms"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D004701",
          "term": "Endocrine Gland Neoplasms"
        },
        {
          "id": "D010049",
          "term": "Ovarian Diseases"
        },
        {
          "id": "D000291",
          "term": "Adnexal Diseases"
        },
        {
          "id": "D005831",
          "term": "Genital Diseases, Female"
        },
        {
          "id": "D052776",
          "term": "Female Urogenital Diseases"
        },
        {
          "id": "D005261",
          "term": "Female Urogenital Diseases and Pregnancy Complications"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D005833",
          "term": "Genital Neoplasms, Female"
        },
        {
          "id": "D014565",
          "term": "Urogenital Neoplasms"
        },
        {
          "id": "D000091662",
          "term": "Genital Diseases"
        },
        {
          "id": "D004700",
          "term": "Endocrine System Diseases"
        },
        {
          "id": "D006058",
          "term": "Gonadal Disorders"
        }
      ]
    }
  },
  "hasResults": false
}